Amundi Asset Management US’s Cidara Therapeutics CDTX Stock Holding History

Amundi Asset Management US’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,680	Closed	-$148K	–	1603
2018 Q3	$148K	Hold	1,680	–	–	﹤0.01%	1485
2018 Q2	$175K	Buy	+1,680	New	+$159K	﹤0.01%	1431

Other funds holding CDTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Amundi Asset Management US's CDTX Position: Q4 2018 in Review

Amundi Asset Management US sold out of Cidara Therapeutics (CDTX) in Q4 2018, closing a stake of 1,680 shares — an estimated $148K sold.

Amundi Asset Management US first reported a position in CDTX in Q2 2018 and held it in 2 quarters. The position peaked at $175K in Q2 2018. 49 funds tracked by Wall St. Rank hold CDTX as of Q4 2018.

Amundi Asset Management US reported no remaining Cidara Therapeutics position as of Q4 2018 after selling out during the quarter.
Amundi Asset Management US sold 1,680 Cidara Therapeutics shares in Q4 2018, an estimated $148K.
Amundi Asset Management US first reported a position in Cidara Therapeutics in Q2 2018 and held it in 2 quarters.
Amundi Asset Management US's Cidara Therapeutics position peaked at $175K in Q2 2018.
49 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.